UK-based Ellipses Pharma, a company progressing cancer treatments through an innovative drug development model, has announced that it is to develop a next-generation immuno-oncology drug which could address the needs of those who do not respond to existing checkpoint inhibitors.
Ellipses has agreed to in-license global rights to GENA-104, a first-in-class monoclonal antibody that targets CNTN4, a recently-discovered checkpoint protein that is highly expressed in a wide range of tumor types.
GENA-104 was first discovered by Genome & Company (Kosdaq: 314130), a South Korea-based biotech focused on discovery and development of novel cancer target antibodies and antibody-drug conjugates (ADCs).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze